Prescribing pattern and adverse drug effects monitoring of anti-rheumatoid drugs in rheumatoid arthritis patients in a tertiary care hospital

M. Venkateswaran, M. Dhanasekaran*, S. Rajavelu

ABSTRACT

Background: Rheumatoid arthritis (RA) is a common disease that causes substantial morbidity in most patients and premature mortality in many. All the drugs used in the treatment of rheumatoid arthritis show significant toxicity and hence it is important to monitor the drugs for adverse drug reaction. This study will estimate the prescribing pattern and bring out the possible adverse drug reactions in patients with rheumatoid arthritis.

Methods: This study included 200 patients with rheumatoid arthritis who fulfilled the study criteria were observed for three months. Their prescriptions were collected and analysed. The symptoms of adverse drug reaction were documented through questionnaire. The causality assessment was done by WHO-UMC assessment scale and severity by using modified Hartwig-Seigel severity assessment scale.

Results: This study showed most of the patients were female (86%). Majority of them were in age group of 51-60 years. Average number of drugs per prescription was 10.57. Out of 200 patients, 2% were on single DMARD and 50.5% were on two DMARDs. 40% and 7.5% were taking three and four DMARDs respectively. A total of 450 adverse drug reactions were reported, out of which 68.4% due to steroid, 12.5% due to DMARDs and 19.1 due to use of NSAIDs, DMARDs and glucocorticosteroids. Chloroquine maculopathy occurred in 3 patients and elevated liver enzymes due to methotrexate in 3 patients, which necessitated DMARD withdrawal. Most patients had 1-3 ADRs. 6% of ADRs were severe and 54% belongs to probable category of causality assessment.

Conclusions: Treatment of rheumatoid arthritis is mainly based on DMARDs, glucocorticosteroids and NSAIDs. So, occurrence of ADR is much common. Proper monitoring of therapy and timely modification of drugs and lifestyle can reduce the ADR occurrence.

Keywords: Adverse drug reactions, Disease modifying anti-rheumatic drug, Glucocorticosteroid, Non-steroidal anti-inflammatory drug, Rheumatoid arthritis

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with polyarthritis and dysfunction of joints. RA affects about 1% of the world population and approximately 0.75% of the adult Indian population. It can occur at any age. But the peak age of onset is more common in 4-5th decade. However, the prevalence of RA increases with age and it is more common in women than men in the ratio of 2:1.

The primary goal of treatment of rheumatoid arthritis should aim to reach clinical remission, to prevent structural damage and to provide improved quality of life in patients. Disease modifying anti-rheumatic drugs...
(DMARDs) are the first line agents used in the treatment for patient with established rheumatoid arthritis. Current management emphasizes the benefits of early disease modifying anti-rheumatic drugs (DMARDs). These agents are characterized by the ability to reduce or reverse the signs and symptoms, disability and improve quality.

DMARDs are classified into biologic and non-biologic or synthetic DMARDs. The non-biologic agents include drugs like hydroxychloroquine, azathioprine, methotrexate, sulphasalazine, leflunomide, cyclophosphamide, gold salt. The biologic DMARDs includes abatacept, rituximab, tocilizumab and Tumor necrosis factor inhibitors.

Non-steriodal anti-inflammatory drugs are used in the treatment of rheumatoid arthritis to reduce the pain and inflammation of joints, but they don’t prevent the progression of disease activity.

Low dose corticosteroids produce a prompt anti-inflammatory effect in rheumatoid arthritis and slow the rate of articular lesion. These often are used as a “bridge” to reduce disease activity until the slower acting DMARDs take effect or as adjunctive therapy for active disease that persists despite treatment with DMARDs. Higher doses are used to manage serious extra-articular manifestations. All patients receiving long term corticosteroid therapy should take measures to prevent osteoporosis.

All the drugs used in the treatment of rheumatoid arthritis show significant toxicity and hence it is very important that their use require regular monitoring for adverse reactions. The present study is design to estimate the prescribing pattern and the occurrence of adverse drug reactions in patients with rheumatoid arthritis.

METHODS

It was a prospective observational study conducted from March 2018 to June 2018 in 200 patients attending Rheumatology OPD in Govt. Mohan Kumaramangalam Medical College Hospital, Salem, Tamilnadu. This study was started after getting Institutional Ethical committee approval. Written informed consent in local vernacular language was obtained from every patient included in the study at the time of enrollment. Patients diagnosed with established rheumatoid arthritis were enrolled in the study. The patients were followed up every week for a period of three months.

Demographic details, medication details and relevant lab investigation data were collected in a specially designed proforma. Prescription of the study patients collected and analysed. The medication details collected from the patients includes name of the drug or drug combination, dosage form, daily dosage, frequency, drugs prescribed by generic or brand name and all the co-prescribed drugs. Questionnaire was used for collecting ADR data (Annexure 1). Casual relationship of the adverse drug effects was done by establishing the temporal association of drug use with adverse drug reaction. Causality assessment was done by using WHO causality assessment scale and Severity assessment was done by using modified Hartwig and Siegel scale.

Data were entered in excel spreadsheet and descriptive statistics was used to analyse the data.

Inclusion criteria

- Age more than 20 years,
- Sex-both male and female patients with established rheumatoid arthritis,
- Patients who are taking anti-rheumotoid drugs for atleast three months,
- Patients who are willing to give informed consent.

Exclusion criteria

- Acute or chronic medical condition requiring hospitalization,
- Pre-existing hepatic or renal dysfunction,
- Pregnancy and lactation,
- Patient not willing to give informed consent.

RESULTS

Out of 429 patients screened, 200 patients met the study criteria were enrolled in the study. 86% of our study populations were females. Majority of the study population were in the age group of 51-60 years (Table 1). 36% of patients were in the age group of 51-60 years, 29% were in 41-50 years, 14% in 61-70 years, 13 % in 31-40%, 5% were less than 30 years and 3% of them were more than 70 years.

Table 1: Age-wise distribution of the patients.

| Age group (years) | Number of patients | Percentage |
|-------------------|--------------------|------------|
| <30               | 10                 | 05%        |
| 31-40             | 26                 | 13%        |
| 41-50             | 58                 | 29%        |
| 51-60             | 72                 | 36%        |
| 61-70             | 28                 | 14%        |
| >70               | 06                 | 03%        |
| total             | 200                | 100%       |

Majority of patients were taking two DMARDs (Table 2) and none of the them were on biologic DMARDs. The average number of drugs for prescription was 10.57. 100% were prescribed by generic names only. 2% (4) of them were taking single DMARD, 50.5% (101) were taking two DMARDs, 40% (80) were taking three DMARDs and 7.5% (15) were taking four DMARDs.

Among the DMARDs, hydroxychloroquine is the commonly prescribed drug in monotherapy and in
combination with other DMARDs (Table 3). The most common two drug combination used was hydroxychloroquine and methotrexate in 43.5% patients, 25% patients were prescribed triple drug therapy consisting of hydroxychloroquine +methotrexate+ sulphasalazine and 4% patients received quadruple drug therapy containing hydroxychloroquine+methotrexate+sulphasalazine+azathioprine. NSAIDs and steroid are prescribed with DMARDs both in monotherapy as well as in combination therapy for suppression of pain.

Out of 200 patients, 165 patients have reported ADR with use of anti-rheumatoid drugs (Table 4). 82.5% patients reported ADR and 17.5% patients were without ADR.

### Table 3: Pattern of combinations of DMARDs.

| Name of the combination                                      | Numbers (%) |
|--------------------------------------------------------------|-------------|
| Hydroxychloroquine+Methotrexate                              | 87 (43.5%)  |
| Hydroxychloroquine+Azathioprine                              | 5 (2.5%)    |
| Hydroxychloroquine+Sulphasalazine                            | 2 (1%)      |
| Hydroxychloroquine+Leflunomide                               | 1 (0.5%)    |
| Methotrexate+Azathioprine                                    | 5 (2.5%)    |
| Methotrexate+Sulphasalazine                                  | 1 (0.5%)    |
| Total                                                         | 101 (50.5%) |
| Hydroxychloroquine+Methotrexate+Azathioprine                 | 9 (4.5%)    |
| Hydroxychloroquine+Methotrexate+Sulphasalazine               | 50 (25%)    |
| Hydroxychloroquine+Methotrexate+Leflunomide                  | 19 (9.5%)   |
| Hydroxychloroquine+Azathioprine+Sulphasalazine               | 1 (0.5%)    |
| Methotrexate+Azathioprine+Leflunomide                        | 1 (0.5%)    |
| Total                                                         | 80 (40%)    |
| Hydroxychloroquine+Methotrexate+Azathioprine+Sulphasalazine | 8 (4%)      |
| Hydroxychloroquine+Methotrexate+Azathioprine+Leflunomide     | 3 (1.5%)    |
| Hydroxychloroquine+Methotrexate+Sulphasalazine+Leflunomide   | 4 (2%)      |
| Total                                                         | 15 (7.5%)   |

### Table 4: Occurrence of adverse drug reactions.

| Patients with or without ADR                        | Number of patients | Percentage |
|-----------------------------------------------------|--------------------|------------|
| Patient with ADR                                    | 165                | 82.5%      |
| Patients without ADR                                | 35                 | 17.5%      |
| total                                               | 200                | 100%       |

A total of 450 adverse drug reaction reports were obtained from 200 patients in this study. Among these, 19.7% were due to insomnia caused by steroid and the second common adverse drug reaction was gastritis which occurred in 18.2% of patient caused by steroid and NSAIDs (Table 5). 19.7% patients had insomnia, 18.2% had gastritis, 16.7% had palpitation, 15.8% had cushingoid features, 9.6% had skin rashes, 8.0% had hypertension, 5.1% had hyperglycemia, 3.1% had presenile cataract, 1.5% had hyperpigmentation, 0.7% had asthma, maculopathy, elevated liver enzymes and 0.2% had aphthous ulcer.

A 26.7% of patients had three ADRs and 20.4% had four ADRs (Table 6). 26.7% patients have three ADRs, 20.4% patients have four ADRs, 18.9% had five ADRs, 16.9% had two ADRs, 9.1% had one ADR and 8.0% patients had six ADRs.

A 63.6% of ADR belongs to mild category of Modified Hartwig and Siegel scale (Table 7). 63.6% patients were mild, 35.1% were moderate and 1.3% were severe category of Modified Hartwig and Siegel scale.

A 54% of ADRs belongs to probable category of causality assessment (Table 8). 46% belongs to possible and 54% belongs to probable and 0% belongs to certain category of causality assessment.
Table 5: Pattern of ADR in patients taking anti-rheumatoid drugs.

| Name of the ADR          | Number of patients | Percentage (%) | Causative drug     | Assessment category |
|--------------------------|--------------------|----------------|--------------------|---------------------|
| Cushingoid features      | 71                 | 15.8%          | Steroid            | Probable            |
| Gastritis                | 82                 | 18.2%          | Steroid+NSAIDs     | Probable            |
| Asthma                   | 3                  | 0.7%           | NSAIDs             | Possible            |
| Hyperpigmentation        | 7                  | 1.5%           | Chloroquine        | Possible            |
| Aphthous ulcer           | 1                  | 0.2%           | NSAIDs, DMARDs     | Possible            |
| Presenile cataract       | 14                 | 3.1%           | Steroid            | Possible            |
| Skin rashes              | 43                 | 9.6%           | DMARDs             | Possible            |
| Insomnia                 | 89                 | 19.7%          | Steroid            | Possible            |
| Palpitation              | 75                 | 16.7%          | Steroid            | Possible            |
| Hypertension             | 36                 | 8.0%           | Steroid            | Probable            |
| Hyperglycemia            | 23                 | 5.1%           | Steroid            | Probable            |
| Maculopathy              | 03                 | 0.7%           | Chloroquine        | Probable            |
| Elevated liver enzymes   | 03                 | 0.7%           | Methotrexate       | Probable            |
| Total                    | 450                | 100%           |                    |                     |

Table 6: Distribution of ADRs.

| Number of ADRs in a Patients | Number of Patient | Total number of ADRs | Percentage (%) |
|------------------------------|-------------------|----------------------|----------------|
| 1                            | 41                | 41                   | 9.1%           |
| 2                            | 38                | 76                   | 16.9%          |
| 3                            | 40                | 120                  | 26.7%          |
| 4                            | 23                | 92                   | 20.4%          |
| 5                            | 17                | 85                   | 18.9%          |
| 6                            | 06                | 36                   | 8.0%           |
| Total                        | 165               | 450                  | 100%           |

Table 7: Severity assessment of ADRs.

| Assessment category | Number of ADRs | Percentage (%) |
|---------------------|----------------|----------------|
| Mild                | 286            | 63.6%          |
| Moderate            | 158            | 35.1%          |
| Severe              | 6              | 1.3%           |
| Total               | 450            | 100%           |

Table 8: Causality assessment of ADRs.

| Certain Category     | Number of ADRs | Percentage (%) |
|----------------------|----------------|----------------|
| Certain              | 0              | 0              |
| Probable             | 243            | 54.0%          |
| Possible             | 207            | 46.0%          |
| Total                | 450            | 100%           |

DISCUSSION

Rheumatoid arthritis is a chronic auto immune inflammatory illness characterized by polyarthritis of small and large joints which in the course of time may progress to disability. Treatment with disease modifying anti rheumatoid drug (DMARD) plays a pivotal role in the management of rheumatoid arthritis.

The study of prescribing pattern and adverse drug reaction monitoring is very essential to provide suitable modifications in prescribing practice so that maximum therapeutic benefits will be obtained with minimal occurrence of adverse drug reaction.

In this study, 200 patients were evaluated for the prescription pattern and adverse drug reaction. Our study revealed that prevalence of Rheumatoid Arthritis was more in female patients 172 (86%) than male patients. Recent study conducted by Mittal et al in India has reported that more than 80% of the RA patients were females, in agreement with our study. The ratio of the disease among female: male is 6.14:1 which is similar to
the study conducted by Owino et al.\textsuperscript{17} This higher ratio can be attributed to the hormonal difference between female and male patients.

The average number of drugs per prescription was 10.57. This is high when compared to the study done by Gawde et al were the average number of drugs per prescription was found to be 6.17 in Mumbai.\textsuperscript{18} As the study was done in government medical college hospital, all the drugs were prescribed by generic name and only non-biologic DMARDs were prescribed to the patients due to the non-availability of biologic DMARDs in the institution.

The overall drug usage describes that two DMARDs (50.5\%) was used in majority of the patients. This is comparable to the study by Kashefi et al, were majority of the patients were on two DMARDs (52.3\%).\textsuperscript{19} The most frequently prescribed DMARDs combination was methotrexate and hydroxychloroquine (43.5\%). According to the ACR 2015 guidelines to treat rheumatoid arthritis recommends that regardless of the disease activity level, combination therapy can be started only when the disease activity remains high in spite of the monotherapy.\textsuperscript{8} Glucocorticoids and NSAIDs were widely used in addition to DMARDs in the study. Drugs like ranitidine, omeprazole, antacid, folic acid, iron, calcium, vitamins and bisphosphonates were given in addition to the standard drugs to manage the adverse drug reaction.

Total of 450 adverse drug reactions were reported in our study. Many patients had 1-3 ADRs. The most common adverse drug reaction is insomnia due to use of steroids. It is followed by gastritis due to use of NSAIDs and steroids. The most serious adverse reaction which was irreversible and required drug withdrawal was chloroquine maculopathy which occurred in 3 patients. The other reaction that required drug withdrawal was elevated liver enzymes due to methotrexate occurred in 3 patients. These results were less compared to adverse drug reaction study done by Machodo et al.\textsuperscript{20}

On assessing severity score, 63.6\% of ADR were only mild in nature, 35.1\% were moderate and 1.3 \% were severe. WHO causality assessment of ADR was done and found that 54\% belongs to probable and 46\% belongs to possible category of assessment.

CONCLUSION

Occurrence of ADR is much common in patients treated for rheumatoid arthritis especially in those associated with Disease modifying anti-rheumatic arthritis drugs. But with proper monitoring and timely modification of drugs and lifestyle, we can reduce the risk in these patients.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Harris ED. Clinical features of rheumatoid arthritis. Kelley’s Textbook of Rheumatology. 7th ed. Saunders Elsevier; Philadelphia; 2005.
2. Gibofsky A. Overview of Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Managed Care. 2012;18 Suppl 13:295-302.
3. Mijiyawa M. Epidemiology and semiology of Rheumatoid arthritis in third world countries. Rev Rhum. 1995;62:121-6.
4. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int. 1993;13:131-4.
5. Schuna A. A Rheumatoid arthritis. In: Joseph DT, Michael PL, Robert TL, Gray YC, Gray MR, Barbara WG. Pharmacotherapy a pathophysiology approach. 7th ed. Mc Graw Hill, New York; 2008:1505-1519.
6. Mota LM, Cruz BA, Brenol CV, Pereira IA, Fronza LS, Bertolo MB, et al. Consensus of the Brazilian society of rheumatology for diagnosis and early assessment of rheumatoid arthritis. Rev Bras Reumatol. 2011;51:207-19.
7. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gäujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75.
8. Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1-26.
9. Dutta SB, Beg MA, Bawa S, Kaur A, Subhash V. Prescribing pattern in rheumatoid arthritis patients in a tertiary care teaching hospital. Int J Basic Clin Pharmacol. 2017;6(6):1486-90.
10. Furst DE, Ulrich RW, Prakash S. Non-steroidal anti-inflammatory drugs, disease modifying anti-rheumatic drugs, non-opioid analgesics and drugs used in gout. In: Katsung BG, Masters SB, Anthony trevor J’s Basic Clin Pharmacol. 12th ed. Mc Graw Hill, New York; 2012:635-659.
11. Chen SW. Rheumatic disorders. In: Koda-Kimble MA, Young LY, Aldredge BK, Corelli RL, Guglielmo JB, Kradjian WA, et al. Applied therapeutics: the clinical use of drugs. 9th Ed. Lippincott Williams and Wilkins, USA; 2009:1168-1208.
12. Hellmann DB, Imboden JB. Rheumatologic, Immunologic and Allergic Disorders. In: Papadakis MA, Mephee SJ, Rabow MW. Lange, Current Medical Diagnosis and Treatment. 55th ed. Mc Graw Hill, New York; 2016:812-868.
13. Bajraktari IH, Teuta BC, Vjolca SM, Bajraktari H, Saiti V, Krasniqi B, Musimi F. Demographic features of patients with rheumatoid arthritis in Kosovo. Medical Archives. 2014 Dec;68(6):407.
14. Singh JA, Furst DE, Bharat A, Curtis IR, Kavanaugh AF, Kremer JM, et al. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Am Coll Rheumatol. 2012;64:625-39.
15. Lakshmi Prabha M, Geetha Rani A, Meenakshi Balasubramanian, Ezhil Ramya J, et al. Prescribing pattern and adverse drug reactions monitoring in patients with rheumatoid arthritis in a tertiary care hospital. Int J Basic Clin Pharmacol. 2016;5(3):805-9.
16. Mittal N, Mittal R, Sharma A, Jose V, Wanchu A, Singh S. Treatment failure with disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients. Singapore Med J. 2012;53(8):532-6.
17. Owino BO, Oyoo GO, Otieno CF. Socio-demographic and clinical aspects of Rheumatoid arthritis. East Afr Med J. 2009;86:204-211.
18. Gawde SR, Shetty YC, Merchant S, Kulkarni UJ, Nadkar MY et al. Drug utilization pattern and cost analysis study in rheumatoid arthritis patients-a cross sectional study in a tertiary care hospital Mumbai in British J Pharma Res. 2013;3(1):37-45.
19. Kashefi S, Lee SM, Mallaysamy S, Thunga PG. Demographic, clinical characteristics and drug prescription pattern in patients with rheumatoid arthritis in south Indian tertiary care hospital. Int J Pharmacy Pharma Sci. 2016;8(8):251-7.
20. Machado J, Ruiz A, Machado-Duque M. Adverse drug reactions associated with the use of disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Value in Health. 2015 May 1;18(3):A153.
Annexure 1: Study questionnaire.

| Name |
|------|
| Age /Sex |
| Address |
| Duration of the disease |
| Other concomitant drug intake | Yes/No |

Do you have the following symptoms?

1) Cushingoid features
   - O Yes
   - O No
   - O don’t Know

2) Gastritis
   - O Yes
   - O No
   - O don’t Know

3) Asthma exacerbation
   - O Yes
   - O No
   - O don’t Know

4) Hyperpigmentation
   - O Yes
   - O No
   - O don’t Know

5) Aphthous ulcer
   - O Yes
   - O No
   - O don’t Know

6) Presenile cataract
   - O Yes
   - O No
   - O don’t Know

7) Skin rashes
   - O Yes
   - O No
   - O don’t Know

8) Insomnia
   - O Yes
   - O No
   - O don’t Know

9) Palpitation
   - O Yes
   - O No
   - O don’t Know

By examination and lab investigations:

1) Hypertension
   - O Yes
   - O No

2) Hyperglycemia
   - O Yes
   - O No

3) Maculopathy
   - O Yes
   - O No

4) Elevated liver enzymes
   - O Yes
   - O No